LifeNet Health has launched, an allograft interbody spacer specifically designed for anterior cervical interbody system (ACIS) instrumentation, becoming the latest generation of its VertiGraft portfolio of allograft implants.
The VertiGraft ACIS VG2 is comprised of a cancellous core and cortical endplates and is engineered to provide mechanical strength, reduce migration, and facilitate early vascularisation and bone remodelling.
The company’s previous allograft implants have enjoyed some clinical effectiveness, LifeNet Health said in a press release. A prospective study found 100% fusion rates after 12 months in 74 anterior cervical discectomy and fusion (ACDF) patients while facilitating bone growth and remodelling.
Heather Pierce, general manager of global spine and general orthopaedics at LifeNet Health, says the device combines structural allograft technology and spinal instrumentation in order to achieve “greater efficiency and flexibility for clinicians and effective healing for patients.”
The VertiGraft ACIS VG2 allograft, which is processed with the company’s in-house Allowash XG and Preservon technologies, can be obtained in multiple footprints, in both parallel and lordotic configurations to adjust for fit, fill, and saggital balance restoration.
The company claims that the cortical endplates provide the necessary strength to support the load of the cervical spine, and the cancellous centre allows for early bone and vascular in–growth; as well as having a chamfered profile design that aims to be easy to insert.